- FREE CONSULTATION & SHIPPING
- NEWEST WEIGHT LOSS PEPTIDE: RETATRUTIDE
- A NEW ERA OF HEALTH, BORN IN THE PHILIPPINES
- FREE CONSULTATION & SHIPPING
- NEWEST WEIGHT LOSS PEPTIDE: RETATRUTIDE
- A NEW ERA OF HEALTH, BORN IN THE PHILIPPINES
Triple Hormone Receptor Agonist · Educational Resource
Understanding Retatrutide and Metabolic Research
Triple Hormone Receptor Agonist
(GLP-1/GIP/Glucagon)
Investigational Application
Metabolic and glucose regulation research
Administration Protocol
Subcutaneous (subQ), weekly interval
Want to learn more?
A licensed team will reach out to guide you through the research.
Book a consultation →Triple Hormone Receptor Agonist · Educational Resource
Understanding Retatrutide and Metabolic Research
01 — Overview
What is Retatrutide?
Retatrutide is a synthetic peptide classified as a triple hormone receptor agonist, engineered to activate GLP-1, GIP, and glucagon receptor pathways simultaneously.
Unlike some compounds in this class, retatrutide has not received regulatory approval in any form and remains under active investigation in clinical trials. It should be understood strictly as a research compound, not an approved therapeutic.
Within research literature, retatrutide is most frequently studied for its multi-pathway role in metabolic regulation, areas summarized further below.
02 — How it works
How It Works: Triple Receptor Activation and Metabolic Signaling
As a triple hormone receptor agonist, retatrutide binds to and activates GLP-1, GIP, and glucagon receptors found in the pancreas, gastrointestinal tract, liver, and areas of the central nervous system associated with appetite and energy regulation.
Literature describes this three-pathway activation, particularly the added glucagon receptor component, as a mechanism studied for its distinct research profile relative to single- or dual-pathway incretin agonists.
Administration in Research
In clinical trial literature, retatrutide is evaluated as a subcutaneous injection administered on a weekly schedule, within controlled dose-escalation study protocols. As an investigational compound, it has not received regulatory approval in any form, and research contexts differ from any at-home or self-directed use.
03 — Areas of research
Summary of Investigated Research Areas
Clinical trial and preclinical literature evaluates retatrutide across several key physiological parameters to map its biological interactions:
Triple Receptor Signaling Pathways
Research literature evaluates how combined GLP-1, GIP, and glucagon receptor activation influences metabolic signaling in study populations.
Appetite and Satiety Signaling
Studies observe central nervous system pathways linked to appetite regulation following multi-receptor agonism.
Energy Expenditure Parameters
Investigational literature examines markers of energy expenditure associated with glucagon receptor co-activation.
Glycemic Regulation Pathways
Clinical trial data evaluates glucose-dependent insulin secretion patterns in study populations.
Body Composition Studies
Research protocols track body composition measures over controlled study periods involving this compound class.
Pharmacokinetic Profiling
Early-phase studies characterize the absorption, distribution, and elimination profile of retatrutide in trial settings.
04 — FAQ
Frequently Asked Questions
Ano ba talaga ang Retatrutide?
Retatrutide is a synthetic peptide na triple hormone receptor agonist, ibig sabihin ino-activate nito ang GLP-1, GIP, at glucagon receptors nang sabay-sabay. Ito ay pinag-aaralan pa rin sa clinical trials at hindi pa naaprubahan sa anumang bansa. Educational discussion lang ito, hindi sales o medical advice.
FDA-approved ba ito?
Hindi pa. Ang Retatrutide ay isang fully investigational compound na wala pang regulatory approval kahit saan sa mundo. Nasa clinical trial stages pa ito.
Ano ang pagkakaiba nito sa Semaglutide at Tirzepatide?
Ang Retatrutide ay dumadagdag ng third pathway (glucagon receptor) sa GLP-1 at GIP na mekanismo, samantalang ang Semaglutide ay GLP-1 lang at ang Tirzepatide ay GLP-1/GIP lang. Ito ay pinag-aaralan bilang mas malawak na multi-receptor approach.
Pwede ba akong bumili nito dito?
Ang page na ito ay para sa educational purposes lamang. Hindi kami nagbebenta ng peptides dito online — kausapin ang isang lisensyadong healthcare provider para sa tamang gabay.
05 — References
References and Academic Literature
Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine.
Rosenstock, J., et al. (2023). Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes. The Lancet.
Sanyal, A.J., et al. (2024). Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease. New England Journal of Medicine.
i
Medical Education Disclaimer: This page is intended strictly for educational and informational purposes regarding the scientific history and development of chemical compounds. It does not constitute medical advice, promotion, or advertising of any prescription medication. Any therapeutic applications must be evaluated and managed exclusively by a licensed medical practitioner.
Getting started
How to Get Started?
1. Consult
Book a free consultation with our licensed healthcare team.
100 % online. Hassle-free. Convenient.
2. Real Human Assessment
Talk with Philippine-licensed doctors and get prescribed.
Always doctor-led—never just an online form.
Free consultation with licensed providers
3. Start your Program
Your medication is prepared and delivered to your doorstep.
No lock-ins. No hidden fees. No subscriptions.
Formulated in FDA-regulated pharmacies
4. Consistent care
Stay on track with regular weekly follow-ups. On your chosen communication platform.
Unlimited complementary follow-ups